TransLink and Xenoislet: Europe is taking the lead in Xenotransplatation

20161109160358

On the 9th of November 2016, the European Collaborative projects TransLink and Xenoislet joined together in a public dissemination event: the Conference on “Research on animal-derived products for use in the clinic – Results from EU collaborative projects”.

Students and international professionals attended the iconic Wilkins Main Building at University College London and got key insights into xenotransplantation for both heart valve deterioration and diabetes treatment from the top experts in the fields.

The conference aimed to promote the international exchange of the latest concepts, innovative techniques and results in the field of cardiovascular valve transplantation, glycoimmunology, pancreatic islets and innovative diabetes treatment, offering participants the opportunity to
interact
with
a
number
of
outstanding scientific leaders and researchers.

Dr Emanuele Cozzi (Azienda Ospedaliera di Padova, Italy) (above, right) and Prof Pierre Gianello (Catholic University of Louvain, Belgium) (above, left), co-ordinators of TransLink and Xenoislet, respectively, led the Conference which gathered experts from hospitals, academia and companies focused on the research, understanding and creation of real solutions inheart valve pathology and diabetes.

Furthermore, the event was attended by Dr Charles Kessler, Research Directorate-General of the European Commission, who provided insight into the thinking of the European Commission and global challenges, as well as the importance of collaborative research for addressing such challenges.

Meet the experts behind our EU collaborative projects, discover their objectives and results:

  • TransLink “Defining the role of xeno-directed and autoimmune events in patients receiving animal-derived bioprosthetic heart valves” and
  • Xenoislet “Macroencapsulated Porcine Pancreatic Islets to cure Diabetes Mellitus type 1/2”